Atricure's epi-sense system approved by fda for treatment of long-standing persistent afib patients

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage (laa) management, today announced u.s. food and drug administration (fda) approval of the epi-sense® system to treat patients diagnosed with long-standing persistent afib. the converge™ trial demonstrated superiority in the hybrid af™ therapy arm compared to endocardial catheter ablation alone. in patients diagnosed with long-standing persistent
ATRC Ratings Summary
ATRC Quant Ranking